DrugPatentWatch Database Preview
Investigational Drug Information for Ibodutant
Email this page to a colleague
What is the development status for investigational drug Ibodutant?
Ibodutant is an investigational drug.
There have been 5 clinical trials for Ibodutant.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Syndrome, Irritable Bowel Syndrome, and Diarrhea. The leading clinical trial sponsors are Menarini Group and [disabled in preview].
There are fourteen US patents protecting this investigational drug and two hundred and fourteen international patents.
Summary for Ibodutant
| US Patents | 14 |
| International Patents | 214 |
| US Patent Applications | 41 |
| WIPO Patent Applications | 45 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2014-03-01) |
| Vendors | 12 |
Recent Clinical Trials for Ibodutant
| Title | Sponsor | Phase |
|---|---|---|
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
Clinical Trial Summary for Ibodutant
Top disease conditions for Ibodutant
Top clinical trial sponsors for Ibodutant
US Patents for Ibodutant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibodutant | ⤷ Sign up for a Free Trial | Compositions and methods for inducing urinary voiding and defecation | Dignify Therapeutics, LLC (Research Triangle Park, NC) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Class of mu-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Compositions and methods for treating or preventing gut permeability-related disorders | Gelesis LLC (Boston, MA) | ⤷ Sign up for a Free Trial |
| Ibodutant | ⤷ Sign up for a Free Trial | Linear basic compounds having NK-2 antagonist activity and formulations thereof | Menarini Ricerche S.P.A. (Pomezia, IT) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibodutant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibodutant | Canada | CA2918245 | 2033-08-01 | ⤷ Sign up for a Free Trial |
| Ibodutant | European Patent Office | EP3027199 | 2033-08-01 | ⤷ Sign up for a Free Trial |
| Ibodutant | Japan | JP2016527271 | 2033-08-01 | ⤷ Sign up for a Free Trial |
| Ibodutant | Japan | JP6570521 | 2033-08-01 | ⤷ Sign up for a Free Trial |
| Ibodutant | World Intellectual Property Organization (WIPO) | WO2015017575 | 2033-08-01 | ⤷ Sign up for a Free Trial |
| Ibodutant | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign up for a Free Trial |
| Ibodutant | Canada | CA3023278 | 2036-05-05 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
